Dapoxetine
Wed,26 October 2011
Dapoxetine is the first oral pharmacologic agent developed specifically for the treatment of men's premature ejaculation. The safety and efficacy of Dapoxetine for the treatment of men with PE were studied in 5, double-blind, placebo- controlled, Phase III clinical trials involving over 6,000 subjects from 30 countries worldwide, including countries in North America, South America, Europe and Asia, and in Israel and South Africa. Janssen-Cilag companies in Europe have submitted a Marketing Authorisation Application for dapoxetine, a treatment for premature ejaculation in men 18-64 years of age.